Sumitomo Mitsui DS Asset Management Company Ltd Purchases 633 Shares of Becton, Dickinson and Company (NYSE:BDX)

Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,045 shares of the medical instruments supplier’s stock after buying an additional 633 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Becton, Dickinson and Company were worth $7,967,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Sound Income Strategies LLC raised its position in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares during the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company during the second quarter valued at approximately $45,000. Abound Wealth Management grew its holdings in shares of Becton, Dickinson and Company by 96.0% in the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 96 shares in the last quarter. Tributary Capital Management LLC purchased a new position in shares of Becton, Dickinson and Company in the first quarter valued at $49,000. Finally, Chilton Capital Management LLC grew its holdings in shares of Becton, Dickinson and Company by 1,233.3% in the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 185 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 1.4 %

Shares of BDX opened at $243.75 on Friday. The firm has a market capitalization of $70.45 billion, a P/E ratio of 53.69, a P/E/G ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $262.23. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The firm has a fifty day moving average price of $237.01 and a 200-day moving average price of $235.28.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business’s revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.96 earnings per share. Equities research analysts expect that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were issued a $0.95 dividend. The ex-dividend date of this dividend was Monday, September 9th. This represents a $3.80 annualized dividend and a dividend yield of 1.56%. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Analyst Ratings Changes

A number of research analysts recently weighed in on BDX shares. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Raymond James cut their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Stifel Nicolaus lifted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, Evercore ISI lifted their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.